Companion Animal Arthritis Market Summary

The global companion animal arthritis market size was valued at USD 3.07 billion in 2022 and is projected to reach USD 5.18 billion by 2030, growing at a CAGR of 6.95% from 2023 to 2030. This notable growth reflects the rising demand for effective veterinary treatments and improved animal healthcare services. The increasing companion animal population, growing prevalence of arthritis, rising risk factors for the disease, supportive awareness programs initiated by governments, and strategies implemented by key companies are some of the key factors driving the market, as pet owners increasingly seek advanced medical solutions to improve animal mobility and quality of life.

For instance, in November 2021, the American Veterinary Medical Association reported that the companion animal population has increased significantly from 2016 to 2020, indicating a strong foundation for market expansion. As per the article, the dog population in the U.S. was estimated at 76.8 million in 2016, which increased to 83.7 million in 2020, reflecting higher adoption rates and improved survival of pets. Similarly, the cat population increased from 58.4 million in 2016 to 60 million in 2020. This consistent rise in companion animals is expected to contribute to market growth by increasing the overall demand for arthritis diagnosis, treatment, and long-term management solutions.

Key Market Trends & Insights

• North America held the largest revenue share of more than 35% in 2022, supported by high pet ownership rates, advanced veterinary infrastructure, and greater awareness regarding companion animal health. The presence of leading market players and favorable reimbursement and insurance frameworks has further strengthened the regional market position.
• The Asia Pacific region is estimated to expand at the highest CAGR of about 8% in the forecast period, driven by rapid urbanization, increasing disposable income, and growing awareness of animal health in countries such as China, India, and Japan. Rising adoption of companion animals and improving access to veterinary services are also contributing to accelerated market growth in the region.
• Based on distribution channel, the veterinary hospitals and clinics segment held the largest revenue share of 35% in 2022, owing to the availability of specialized diagnostic facilities, professional veterinary expertise, and comprehensive treatment options under one roof.
• In terms of treatment, the medication segment held the largest revenue share of over 55.0% in 2022, as pharmaceutical therapies remain the primary approach for managing pain, inflammation, and disease progression in companion animals with arthritis.
• Based on indication, the osteoarthritis segment dominated the market in 2022 with a revenue share of over 75.0% and is estimated to grow the fastest at a rate of about 8% during the forecast period, due to its high prevalence among aging companion animals and increased awareness of early diagnosis and treatment.

Order a free sample PDF of the Companion Animal Arthritis Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2022 Market Size: USD 3.07 Billion
• 2030 Projected Market Size: USD 5.18 Billion
• CAGR (2023-2030): 6.95%
• North America: Largest market in 2022
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

The market is competitive. Leading players deploy various strategic initiatives including competitive pricing strategies, partnerships, product and service expansion, sales and marketing initiatives, and mergers & acquisitions. For instance, in January 2022, Zoetis received FDA approval for Solentia, a monoclonal antibody injection in the U.S. This frunevetmab injection is intended for osteoarthritis pain in cats. Similarly, the new manufacturing units launched by the key companies are enhancing their overall industry presence.  For instance, in April 2022, Elanco collaborated with Ginkgo Bioworks to launch a new veterinary company BiomEdit. This was opened to introduce engineered microbes and probiotics in veterinary care services. Such initiatives by organizations and companies are propelling market growth. 

Key Players

• Zoetis
• Virbac
• Elanco
• Boehringer Ingelheim International GmbH
• Ceva
• Dechra Pharmaceuticals PLC.
• Vetoquinol
• NexGen Pharmaceuticals
• Norbrook
• Eltech K-Laser s.r.l.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The companion animal arthritis market is poised for strong growth, driven by increasing pet populations, rising disease prevalence, and improving awareness of animal health worldwide. Supportive government initiatives, expanding veterinary infrastructure, and advancements in medication-based treatments are enhancing disease management outcomes. Regional growth patterns highlight North America’s established market leadership and Asia Pacific’s rapid expansion potential. The dominance of osteoarthritis and medication-based treatments reflects current clinical practices and unmet needs. Overall, continued investment in veterinary care, diagnostics, and therapeutic innovations will support sustained market expansion and improved quality of life for companion animals globally.